BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 11, 2010
 |  BC Week In Review  |  Company News  |  Deals

Cortex Pharmaceuticals, Merck deal

Merck returned to Cortex rights to develop and commercialize Ampakine compounds to treat schizophrenia and depression as part of an ongoing prioritization process by the...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >